It generated a total sale of Rs3,08,408.60 crore, including Rs1,98,509.49 crore in exports since inception till Sept 2025
In an official statement, the Ministry of Chemicals and Fertilisers stated that under the PMBJP, 2,202 Jan Aushadhi Kendras (JAKs) were opened in 2025, taking the total number to 17,610 since launch.
These centres, implemented through the Pharmaceuticals & Medical Devices Bureau of India (PMBI), provide generic versions of branded medicines at affordable prices.
The PMBJP comprises 2,110 medicines, and 315 medical devices and consumables covering 29 therapeutic groups such as anti-infectives, anti-diabetics, cardiovascular, anti-cancers, gastro-intestinal medicines, etc.
“In 2024-25, the PMBI registered sales of Rs2,022.47 crore, which led to savings of approximately Rs8,000 crore to the citizens,” the ministry said.
“In the current financial year 2025-26, till November, the PMBI has made sales of Rs1,409.32 crore, which has led to savings of approximately Rs5,637 crore to the citizens,” it added.
The PLI Scheme for pharmaceuticals supports the manufacturing of high-value products like biopharmaceuticals, complex generics, patented/off-patent drugs, orphan, and autoimmune drugs.
“It generated a total sale of Rs3,08,408.60 crore, including Rs1,98,509.49 crore in exports since inception till September 2025,” the statement said.
Further, investment worth Rs 40,294 crore has also been made under the scheme till September 2025. The amount significantly exceeded the targeted investment of Rs17,275 crore.
The PLI scheme for the promotion of domestic manufacturing also helped reduce the import dependence for bulk drugs.
“Thirty per cent of India’s overall bulk drug exports and 26.5 per cent of overall formulation exports in FY 2025 have been contributed through production under the scheme,” the statement said.
